Agreements
GlaxoSmithKline Brasil (GSK) Versão em português
FAPESP and GlaxoSmithKline Brasil, GSK hereby agree to support a collaborative program, with the aim of promoting and supporting research projects involving collaboration between scientists working in public or private research or teaching institutions in the State of São Paulo, Brasil and scientists from GSK.
The research projects should create new knowledge, contribute to build up scientific and technological competencies, foster strategic alliances for scientific and technological development, promote the dissemination of knowledge and generate results which potentially could lead to applications with market value in the area(s) of interest to FAPESP and GSK.
Cooperation agreement between FAPESP, GlaxoSmithklineBrasil and Embassy of the United Kingdom of Great Britain and Northern Ireland - Signed on November 19, 2018, with a validity of three years.
Cooperation agreement between FAPESP, GlaxoSmithklineBrasil and Fundação Biominas - Signed on July 31, 2018, with a validity of five years (agreement under revision).
Cooperation agreement - Signed on June 24, 2014, with a validity of ten years.
Cooperation agreement - Signed on October 24, 2013, with a validity of ten years.
Cooperation agreement - Signed on February 28, 2012, with a validity of three years.
Letter of intent - Signed in October, 2011.
CALL FOR PROPOSALS
-
GSK-FAPESP Engineering Research Center in Oncology New Target Discovery (CONTD) - 2020
-
Call for proposals FAPESP, GSK and Biominas (under revision)
SUPPORTED CENTERS
Center of Excellence in New Target Discovery
CCentre of Excellence for Research in Sustainable Chemistry
Research projects selected in joint calls with FAPESP